HLA-C and cancer: Due to MHC restriction, there are some limitations of eTCR therapy, including the following: (1) cancer cells can avoid T cell recognition by downregulating MHC molecules, rendering themselves invisible to T cells, (2) there is a lack of antigen diversity, and (3) TCR therapy is dependent on the compatibility and availability of MHC molecules, which vary between individuals [24].